Tempus
Tempus Signs $200M Deal With AstraZeneca, Pathos AI to Develop Multimodal Cancer Foundation Model
The collaboration, under which Tempus will collect data licensing and model development fees, will leverage its repository of de-identified multimodal patient data.
Tempus AI Acquires Clinical Trial Patient Matching Firm Deep 6 AI
Pasadena, California-based Deep 6 AI matches patients to clinical trials by mining real-time structured and unstructured electronic medical record data.
Tempus, IFLI Partner to Accelerate Development of Follicular Lymphoma Therapies
The collaboration will involve making a real-world multimodal dataset available in Tempus' Lens platform that researchers can use to accelerate treatment development.
Tempus, Genialis Partner to Develop RNA-Based Cancer Biomarker Algorithms
Genialis will use Tempus' multimodal dataset to develop new RNA-based algorithms for a variety of cancers.
Personalis, Tempus Expand MRD Diagnostics Partnership to Include Biopharma
Tempus will now offer Personalis' NeXT Personal Dx minimal residual disease assay to pharmaceutical and biotech customers.